Is kratom an opioid? What it does to your mu-receptors

At a glance: is kratom an opioid?

Key Takeaways

• Kratom is not an opiate but functions as an opioid. It comes from a plant unrelated to the poppy, yet its alkaloids bind mu-opioid receptors the same way morphine does.
• The brain responds to receptor activation, not to botanical origin. Mitragynine and 7-OH produce opioid-type effects because they act on the opioid system, regardless of what plant they came from.
• Kratom is a partial agonist at the mu-opioid receptor. This means it activates the receptor less completely than morphine, which is one reason kratom leaf rarely causes fatal respiratory depression on its own. But this margin is not a guarantee of safety.
• Concentrated 7-OH does not share the same safety margin as leaf. High-potency 7-OH products can produce dose-dependent respiratory depression similar to classical opioids.
• The opioid receptor connection is also why buprenorphine treats kratom and 7-OH dependence. It is a high-affinity partial agonist at the same receptor, which lets it stabilize withdrawal and cravings.

Opiate vs. opioid: why the distinction matters

The terms are often used interchangeably, but they are not the same.

An opiate is a compound that comes directly from the opium poppy (Papaver somniferum). Morphine and codeine are opiates; they are extracted from poppy resin. Heroin is made by chemically modifying morphine, so it is technically an opioid derived from an opiate.

An opioid is any substance, natural, semi-synthetic, or fully synthetic, that acts on opioid receptors in the body. The receptor interaction is what defines the category, not the source. Fentanyl is a synthetic opioid with no botanical origin at all. Buprenorphine is derived from a poppy alkaloid (thebaine) but modified in a laboratory. Both are opioids because of what they do, not where they come from.

Kratom is neither a poppy plant nor poppy-derived. But its alkaloids bind opioid receptors. A 2020 review in the journal Pain and Therapy (Springer) described kratom's active compounds as "atypical opioids to distinguish them from morphine, semisynthetic opioids, and endogenous ligands," noting that while structurally distinct, they produce "partially overlapping but nonidentical effects."

The FDA's framing is direct: kratom's main alkaloids bind the same mu-opioid receptors as opioid drugs like codeine.

Kratom is not an opiate and is not formally classified as a scheduled opioid drug. But its active compounds act on opioid receptors, so it produces opioid-like effects including pain relief, sedation, euphoria, dependence, and withdrawal.

What kratom does to your mu-opioid receptors

Mitragynine: the dominant alkaloid

Mitragynine makes up roughly 60 to 70% of the total alkaloid content in kratom leaf. It binds primarily to mu-opioid receptors, where it acts as a partial agonist. Partial agonism means it activates the receptor, but less completely than a full agonist like morphine would. The 2020 Springer Pain and Therapy review confirmed that mitragynine "behaves as a partial agonist at mu-receptors and a competitive antagonist at delta- and kappa-opioid receptors."

Partial activation is why the effects of kratom leaf at lower doses feel more stimulating than sedating, and why escalating the dose does not keep increasing the opioid effect indefinitely. There is a ceiling point beyond which more mitragynine produces diminishing additional receptor activation.

7-OH: the more potent alkaloid

7-Hydroxymitragynine (7-OH) is present in kratom leaf only at trace levels (0.003 to 0.04% by dry weight), but it binds to mu-opioid receptors with much higher affinity than mitragynine. The 2020 Springer review described 7-OH as producing "more potent opioid activity" than mitragynine in preclinical models.

There is also a metabolic dimension: the body converts some mitragynine to 7-OH through liver enzyme activity. This means that when someone uses kratom leaf, a portion of the opioid effect comes from 7-OH formed in the body rather than from the leaf directly.

The biased agonism hypothesis

The Springer Pain and Therapy review noted something potentially important about how kratom alkaloids interact with mu-opioid receptors: "unlike traditional opioids, the activation of GPCRs by indole alkaloids does not initiate the beta-arrestin pathway."

This matters because the beta-arrestin pathway has been associated with some opioid side effects, including respiratory depression. The hypothesis is that by preferentially activating the G-protein pathway while not initiating beta-arrestin signaling, kratom alkaloids might produce opioid-like analgesia with a different side-effect profile than classical full agonists.

This is an active and debated area of research. Whether biased agonism fully explains the ceiling on kratom leaf's respiratory effects is not settled. Other researchers have noted that partial agonism alone may account for the safety difference, without requiring a biased-signaling explanation. Both mechanisms may contribute. The clinical implication is the same either way: kratom leaf has a safer respiratory profile than classical opioids, but concentrated 7-OH changes that picture.

The ceiling effect, and where concentrated 7-OH breaks it

The partial agonism and possible biased signaling in kratom leaf mean there is a practical ceiling on how much respiratory depression the leaf itself can cause. This is one of the pharmacological reasons that fatal overdose from kratom leaf alone is less common than from heroin or oxycodone.

That ceiling does not extend to concentrated 7-OH products. The FDA's 2025 scientific assessment documented that 7-OH produces respiratory depression with more than three times the potency of morphine in preclinical studies. A peer-reviewed 2025 pharmacology study confirmed dose-dependent respiratory depression from 7-OH that was reversible with naloxone.

The mechanism is the same, but the dose and form change the danger dramatically.

Kratom leaf is not safe. It still produces physical dependence, withdrawal, and health effects documented in the clinical literature. The ceiling effect reduces one specific risk (respiratory depression), not all risks. Concentrated 7-OH products carry that respiratory risk back in full.

Same receptors, real dependence

Any substance that repeatedly activates mu-opioid receptors will produce physical dependence over time. The brain adapts to the presence of opioid stimulation by adjusting its own baseline receptor activity. When the substance is removed, that adjustment becomes apparent as withdrawal: muscle aches, sweating, anxiety, insomnia, diarrhea, and intense cravings.

Kratom produces this pattern. A 2026 AIM Clinical Cases paper (Annals of Internal Medicine) noted that kratom and 7-OH dependence resembles opioid use disorder clinically, and that best practice is to apply buprenorphine treatment of a similar duration to what is used for OUD.

The receptor logic explains why buprenorphine works for kratom and 7-OH dependence:

Buprenorphine is itself a high-affinity partial agonist at the mu-opioid receptor. It binds tightly enough to prevent withdrawal and reduce cravings, but its partial activation limits sedation and respiratory risk. When someone dependent on 7-OH or kratom takes buprenorphine, it occupies the same receptors that 7-OH was stimulating, which is why withdrawal stabilizes. The same receptor system that created the problem is what the treatment works on.

Buprenorphine/naloxone (Suboxone) is FDA-approved for opioid use disorder and accessible through telehealth in most states. Learn how Bicycle Health's treatment works.

Frequently Asked Questions

Is kratom an opiate?

No. Kratom comes from the tree Mitragyna speciosa, which is native to Southeast Asia and is completely unrelated to the opium poppy. Opiates are compounds derived from poppy resin (morphine, codeine, heroin). Kratom is not an opiate. However, its alkaloids act on opioid receptors, which is why it produces effects that resemble opiates and why dependence on it is treated similarly.

Is kratom classified as an opioid?

Not formally by regulatory classification in the U.S. as of July 2026, though the DEA has filed notices of intent to temporarily schedule concentrated 7-OH. Pharmacologically, kratom's alkaloids act as atypical opioids at mu-opioid receptors, and the FDA and peer-reviewed literature describe them in opioid terms. The absence of a formal classification does not mean the receptor activity is absent.

Does kratom show up as an opioid on a drug test?

No. Kratom alkaloids are structurally distinct from morphine-class opioids and do not cross-react with standard opiate immunoassays at typical use concentrations. They will not cause a positive result on a standard DOT or employer drug screen's opioid panel. A specialized kratom assay can detect them when specifically ordered.

Can you get addicted to kratom?

Yes. Repeated mu-opioid receptor activation produces physical dependence regardless of the source. People who use kratom regularly, particularly concentrated 7-OH products, develop tolerance and experience opioid-type withdrawal when they stop. A 2025 Journal of Addiction Medicine case report documented a patient requiring inpatient medically managed withdrawal after stopping daily 7-OH use, with COWS scores indicating moderate withdrawal.

Why does buprenorphine treat kratom dependence?

Buprenorphine is a high-affinity partial agonist at the mu-opioid receptor, which is the same receptor kratom alkaloids act on. It stabilizes the receptor system that kratom was activating, preventing withdrawal and reducing cravings. A 2026 Annals of Internal Medicine clinical cases paper described buprenorphine as the preferred treatment for kratom and 7-OH dependence, citing its known safety profile and established efficacy for opioid use disorder.

Is 7-OH an opioid?

Yes, pharmacologically. The FDA's 2025 scientific assessment described 7-OH as a "novel potent opioid" that acts through mu-opioid receptor pathways consistent with classical opioids. Its receptor behavior is the basis for the DEA's July 2026 notices of intent to temporarily place concentrated 7-OH in Schedule I. At the receptor level, 7-OH is an opioid.